Is SVRA or IPSC more profitable?

Century Therapeutics' return on equity of -49.51% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% Century Therapeutics N/A -49.51% -38.09%

Does the media refer more to SVRA or IPSC?

In the previous week, Savara had 2 more articles in the media than Century Therapeutics. MarketBeat recorded 8 mentions for Savara and 6 mentions for Century Therapeutics. Savara's average media sentiment score of 0.16 beat Century Therapeutics' score of -0.09 indicating that Savara is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Century Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is AKTS or IPSC more profitable?

Aktis Oncology's return on equity of 0.00% beat Century Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A Century Therapeutics N/A -49.51% -38.09%

Does the media refer more to AKTS or IPSC?

In the previous week, Aktis Oncology and Aktis Oncology both had 6 articles in the media. Aktis Oncology's average media sentiment score of 0.01 beat Century Therapeutics' score of -0.09 indicating that Aktis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Century Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MLTX or IPSC more profitable?

Century Therapeutics' return on equity of -49.51% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets MoonLake Immunotherapeutics N/A -82.53% -58.17% Century Therapeutics N/A -49.51% -38.09%

Does the media favor IPSC or KURA?

In the previous week, Century Therapeutics and Century Therapeutics both had 6 articles in the media. Kura Oncology's average media sentiment score of 0.31 beat Century Therapeutics' score of -0.09 indicating that Kura Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Century Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Kura Oncology 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, ANL or IPSC?

Century Therapeutics has higher revenue and earnings than Adlai Nortye. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 201.19 -$35.53M N/A N/A Century Therapeutics $109.16M 2.44 -$9.58M -$0.93 N/A

Is ANL or IPSC more profitable?

Adlai Nortye's return on equity of 0.00% beat Century Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Century Therapeutics N/A -49.51% -38.09%

Does the media refer more to ANL or IPSC?

In the previous week, Adlai Nortye had 4 more articles in the media than Century Therapeutics. MarketBeat recorded 10 mentions for Adlai Nortye and 6 mentions for Century Therapeutics. Adlai Nortye's average media sentiment score of 0.62 beat Century Therapeutics' score of -0.09 indicating that Adlai Nortye is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Century Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Century Therapeutics (IPSC) Competitors

$1.47 +0.01 (+0.68%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.40 -0.07 (-4.76%)

As of 10/9/2026 07:37 PM Eastern

Compare

IPSC vs. SVRA, AKTS, MLTX, KURA, and ANL

Should you buy Century Therapeutics stock or one of its competitors? Century Therapeutics's main competitors and comparable companies include Savara (SVRA), Aktis Oncology (AKTS), MoonLake Immunotherapeutics (MLTX), Kura Oncology (KURA), and Adlai Nortye (ANL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Century Therapeutics compare to Savara?

Savara (NASDAQ:SVRA) and Century Therapeutics (NASDAQ:IPSC) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Century Therapeutics' return on equity of -49.51% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
Century Therapeutics	N/A	-49.51%	-38.09%

Savara presently has a consensus price target of $10.25, indicating a potential upside of 108.33%. Century Therapeutics has a consensus price target of $4.75, indicating a potential upside of 223.13%. Given Century Therapeutics' higher possible upside, analysts clearly believe Century Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Savara had 2 more articles in the media than Century Therapeutics. MarketBeat recorded 8 mentions for Savara and 6 mentions for Century Therapeutics. Savara's average media sentiment score of 0.16 beat Century Therapeutics' score of -0.09 indicating that Savara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Century Therapeutics has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
Century Therapeutics	$109.16M	2.44	-$9.58M	-$0.93	N/A

87.9% of Savara shares are held by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are held by institutional investors. 5.3% of Savara shares are held by insiders. Comparatively, 2.4% of Century Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Savara has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market.

Summary

Savara beats Century Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Century Therapeutics compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Century Therapeutics (NASDAQ:IPSC) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

In the previous week, Aktis Oncology and Aktis Oncology both had 6 articles in the media. Aktis Oncology's average media sentiment score of 0.01 beat Century Therapeutics' score of -0.09 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Century Therapeutics has higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	150.09	-$63.73M	-$0.82	N/A
Century Therapeutics	$109.16M	2.44	-$9.58M	-$0.93	N/A

Aktis Oncology's return on equity of 0.00% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Century Therapeutics	N/A	-49.51%	-38.09%

Aktis Oncology presently has a consensus target price of $35.63, suggesting a potential upside of 96.28%. Century Therapeutics has a consensus target price of $4.75, suggesting a potential upside of 223.13%. Given Century Therapeutics' higher possible upside, analysts plainly believe Century Therapeutics is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

28.8% of Aktis Oncology shares are held by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are held by institutional investors. 3.3% of Aktis Oncology shares are held by company insiders. Comparatively, 2.4% of Century Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Aktis Oncology beats Century Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Century Therapeutics compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Century Therapeutics (NASDAQ:IPSC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

93.8% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are owned by company insiders. Comparatively, 2.4% of Century Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

MoonLake Immunotherapeutics presently has a consensus price target of $28.50, suggesting a potential upside of 163.40%. Century Therapeutics has a consensus price target of $4.75, suggesting a potential upside of 223.13%. Given Century Therapeutics' higher possible upside, analysts plainly believe Century Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.43
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Century Therapeutics' return on equity of -49.51% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%
Century Therapeutics	N/A	-49.51%	-38.09%

MoonLake Immunotherapeutics has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market.

In the previous week, Century Therapeutics had 1 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 6 mentions for Century Therapeutics and 5 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.30 beat Century Therapeutics' score of -0.09 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Century Therapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A
Century Therapeutics	$109.16M	2.44	-$9.58M	-$0.93	N/A

Summary

Century Therapeutics beats MoonLake Immunotherapeutics on 9 of the 13 factors compared between the two stocks.

How does Century Therapeutics compare to Kura Oncology?

Century Therapeutics (NASDAQ:IPSC) and Kura Oncology (NASDAQ:KURA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Century Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Century Therapeutics' return on equity of -49.51% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.51%	-38.09%
Kura Oncology	-384.30%	-207.18%	-45.17%

Century Therapeutics has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	2.44	-$9.58M	-$0.93	N/A
Kura Oncology	$67.48M	13.97	-$278.67M	-$3.37	N/A

Century Therapeutics has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

Century Therapeutics currently has a consensus target price of $4.75, suggesting a potential upside of 223.13%. Kura Oncology has a consensus target price of $25.69, suggesting a potential upside of 142.33%. Given Century Therapeutics' higher probable upside, analysts plainly believe Century Therapeutics is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

In the previous week, Century Therapeutics and Century Therapeutics both had 6 articles in the media. Kura Oncology's average media sentiment score of 0.31 beat Century Therapeutics' score of -0.09 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kura Oncology	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

50.2% of Century Therapeutics shares are held by institutional investors. 2.4% of Century Therapeutics shares are held by company insiders. Comparatively, 7.6% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Century Therapeutics beats Kura Oncology on 10 of the 15 factors compared between the two stocks.

How does Century Therapeutics compare to Adlai Nortye?

Adlai Nortye (NASDAQ:ANL) and Century Therapeutics (NASDAQ:IPSC) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are held by institutional investors. 2.4% of Century Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Century Therapeutics has higher revenue and earnings than Adlai Nortye.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	201.19	-$35.53M	N/A	N/A
Century Therapeutics	$109.16M	2.44	-$9.58M	-$0.93	N/A

Adlai Nortye presently has a consensus target price of $29.50, suggesting a potential upside of 88.86%. Century Therapeutics has a consensus target price of $4.75, suggesting a potential upside of 223.13%. Given Century Therapeutics' higher possible upside, analysts plainly believe Century Therapeutics is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Adlai Nortye's return on equity of 0.00% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Century Therapeutics	N/A	-49.51%	-38.09%

Adlai Nortye has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market.

In the previous week, Adlai Nortye had 4 more articles in the media than Century Therapeutics. MarketBeat recorded 10 mentions for Adlai Nortye and 6 mentions for Century Therapeutics. Adlai Nortye's average media sentiment score of 0.62 beat Century Therapeutics' score of -0.09 indicating that Adlai Nortye is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Adlai Nortye beats Century Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Century Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IPSC vs. The Competition

Export

Metric	Century Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$264.37M	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	-1.58	13.42	274.15	26.16
Price / Sales	2.44	1,234.38	635.98	112.53
Price / Cash	109.78	116.56	76.38	53.09
Price / Book	0.81	17.17	11.21	6.34
Net Income	-$9.58M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-3.92%	-1.33%	-0.90%	-1.41%
1 Month Performance	-24.23%	-8.44%	-4.44%	-3.48%
1 Year Performance	158.48%	14.02%	6.96%	1.16%

Century Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IPSC Century Therapeutics	1.9651 of 5 stars	$1.47 +0.7%	$4.75 +223.1%	+146.2%	$264.37M	$109.16M	N/A	78
SVRA Savara	2.2807 of 5 stars	$4.68 -2.2%	$10.00 +113.9%	+43.9%	$960.53M	N/A	N/A	70	News Coverage Analyst Forecast
AKTS Aktis Oncology	2.5976 of 5 stars	$17.84 -3.7%	$35.63 +99.7%	N/A	$959.65M	$10.06M	N/A	79	News Coverage
MLTX MoonLake Immunotherapeutics	2.6743 of 5 stars	$10.97 -3.6%	$28.50 +159.7%	+15.4%	$934.08M	N/A	N/A	130
KURA Kura Oncology	3.6358 of 5 stars	$10.43 -1.8%	$25.69 +146.4%	+3.4%	$927.42M	$77.23M	N/A	260

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IPSC) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Century Therapeutics (IPSC) Competitors

IPSC vs. SVRA, AKTS, MLTX, KURA, and ANL

How does Century Therapeutics compare to Savara?

Summary

How does Century Therapeutics compare to Aktis Oncology?

Summary

How does Century Therapeutics compare to MoonLake Immunotherapeutics?

Summary

How does Century Therapeutics compare to Kura Oncology?

Summary

How does Century Therapeutics compare to Adlai Nortye?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC vs. The Competition

Century Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Century Therapeutics (IPSC) Competitors

IPSC vs. SVRA, AKTS, MLTX, KURA, and ANL

How does Century Therapeutics compare to Savara?

Is SVRA or IPSC more profitable?

Do analysts recommend SVRA or IPSC?

Does the media refer more to SVRA or IPSC?

Which has preferable earnings & valuation, SVRA or IPSC?

Do institutionals and insiders believe in SVRA or IPSC?

Which has more volatility & risk, SVRA or IPSC?

Summary

How does Century Therapeutics compare to Aktis Oncology?

Does the media refer more to AKTS or IPSC?

Which has higher earnings and valuation, AKTS or IPSC?

Is AKTS or IPSC more profitable?

Do analysts rate AKTS or IPSC?

Do institutionals & insiders hold more shares of AKTS or IPSC?

Summary

How does Century Therapeutics compare to MoonLake Immunotherapeutics?

Do institutionals and insiders have more ownership in MLTX or IPSC?

Do analysts prefer MLTX or IPSC?

Is MLTX or IPSC more profitable?

Which has more risk & volatility, MLTX or IPSC?

Does the media refer more to MLTX or IPSC?

Which has higher valuation & earnings, MLTX or IPSC?

Summary

How does Century Therapeutics compare to Kura Oncology?

Is IPSC or KURA more profitable?

Which has higher valuation and earnings, IPSC or KURA?

Which has more volatility and risk, IPSC or KURA?

Do analysts prefer IPSC or KURA?

Does the media favor IPSC or KURA?

Do insiders & institutionals have more ownership in IPSC or KURA?

Summary

How does Century Therapeutics compare to Adlai Nortye?

Do institutionals and insiders hold more shares of ANL or IPSC?

Which has better earnings & valuation, ANL or IPSC?

Do analysts prefer ANL or IPSC?

Is ANL or IPSC more profitable?

Which has more volatility & risk, ANL or IPSC?

Does the media refer more to ANL or IPSC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC vs. The Competition

Century Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools